Nxera Pharma Co., Ltd.

TSE:4565 Stock Report

Market Cap: JP¥94.2b

Nxera Pharma Management

Management criteria checks 2/4

Nxera Pharma's CEO is Chris Cargill, appointed in Mar 2022, has a tenure of 2.83 years. directly owns 0.046% of the company’s shares, worth ¥43.69M. The average tenure of the management team and the board of directors is 2.8 years and 5.8 years respectively.

Key information

Chris Cargill

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2.8yrs
CEO ownership0.05%
Management average tenure2.8yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Sep 25
Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Jun 26
Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Is Nxera Pharma (TSE:4565) A Risky Investment?

Apr 06
Is Nxera Pharma (TSE:4565) A Risky Investment?

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Mar 08
Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

CEO Compensation Analysis

How has Chris Cargill's remuneration changed compared to Nxera Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-JP¥4b

Jun 30 2024n/an/a

-JP¥10b

Mar 31 2024n/an/a

-JP¥9b

Dec 31 2023n/an/a

-JP¥7b

Sep 30 2023n/an/a

-JP¥3b

Jun 30 2023n/an/a

JP¥2b

Mar 31 2023n/an/a

JP¥1b

Dec 31 2022JP¥292mJP¥88m

JP¥382m

Sep 30 2022n/an/a

-JP¥383m

Jun 30 2022n/an/a

-JP¥224m

Mar 31 2022n/an/a

JP¥100m

Dec 31 2021JP¥231mJP¥65m

JP¥1b

Sep 30 2021n/an/a

JP¥1b

Jun 30 2021n/an/a

JP¥1b

Mar 31 2021n/an/a

JP¥1b

Dec 31 2020JP¥157mJP¥53m

JP¥1b

Sep 30 2020n/an/a

-JP¥2b

Jun 30 2020n/an/a

-JP¥1b

Mar 31 2020n/an/a

-JP¥332m

Dec 31 2019JP¥101mJP¥40m

JP¥1b

Compensation vs Market: Insufficient data to establish whether Chris's total compensation is reasonable compared to companies of similar size in the JP market.

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Cargill (40 yo)

2.8yrs

Tenure

JP¥292,000,000

Compensation

Mr. Christopher Cargill, also known as Chris, serves as Representative Executive Officer, President, Chief Executive Officer and Director at Nxera Pharma Co., Ltd. (formerly known as Sosei Group Corporatio...

Leadership Team

NamePositionTenureCompensationOwnership
Shinichi Tamura
Founder & Chairman of the Board19.6yrsJP¥332.00m0.66%
¥ 622.8m
Christopher Cargill
Representative Executive Officer2.8yrsJP¥292.00m0.046%
¥ 43.7m
Hironoshin Nomura
Executive Officer2.8yrsno datano data
Toshihiro Maeda
Executive VP & COO1.1yrsno datano data
Kieran Johnson
Executive Officer2.8yrsno datano data
Kazuhiko Yoshizumi
Executive Officer7yrsno datano data
Shinichiro Nishishita
VP of Investor Relations & Head of Regulatory Disclosuresno datano datano data
Stacey Southall
Associate Director & Head of Biophysicsno datano datano data
Candelle Chong
Executive Officer1.8yrsno datano data
Patrick Branch
Head of Business Development for Japan and the APAC regionless than a yearno datano data
Makoto Sugita
President of Nxera Pharma Japan & Exe Officerless than a yearno datano data
Matthew Barnes
Hd. of Drug Disc. & UK R&D2.8yrsno datano data

2.8yrs

Average Tenure

48yo

Average Age

Experienced Management: 4565's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shinichi Tamura
Founder & Chairman of the Board19.6yrsJP¥332.00m0.66%
¥ 622.8m
Christopher Cargill
Representative Executive Officer2.8yrsJP¥292.00m0.046%
¥ 43.7m
Malcolm Weir
Member of Scientific Advisory Board1.3yrsJP¥134.00mno data
Rolf Kristian Berndtson Soderstrom
Independent External Director4.8yrsno data0.016%
¥ 15.0m
Tomohiro Tohyama
Independent External Director13.6yrsno data0.057%
¥ 53.7m
Noriaki Nagai
External Independent Director5.8yrsno data0.038%
¥ 35.8m
Kuniaki Kaga
Independent External Director6.6yrsno data0.040%
¥ 37.3m
David Roblin
Independent External Director6.6yrsno data0.0073%
¥ 6.8m
Paul Leeson
Member of Scientific Advisory Boardno datano datano data
Peter Bernstein
Member of Scientific Advisory Boardno datano datano data
Richard Henderson
Member of Scientific Advisory Boardno datano datano data
Miwa Seki
External Independent Director2.8yrsno data0.013%
¥ 11.8m

5.8yrs

Average Tenure

66yo

Average Age

Experienced Board: 4565's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 01:31
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nxera Pharma Co., Ltd. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Koichi MameganoBofA Global Research
Hidemaru YamaguchiCitigroup Inc
null nullCredit Suisse